PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34861585-9	2022	The circulating level of IL-6 but not TNF-alpha was significantly decreased by AL.	alantolactone	79-81	interleukin 6	Mus musculus	25-29	
34861585-12	2022	AL also ameliorated C2C12 myotube atrophy induced by IL-6 and inhibited IL-6-mediated STAT3 activation.	alantolactone	0-2	interleukin 6	Mus musculus	53-57	
34861585-12	2022	AL also ameliorated C2C12 myotube atrophy induced by IL-6 and inhibited IL-6-mediated STAT3 activation.	alantolactone	0-2	interleukin 6	Mus musculus	72-76	
33556301-7	2021	RESULTS: In CIA mice, alantolactone at 50 mg/kg attenuated RA symptoms, including high arthritis scores, infiltrating inflammatory cells, synovial hyperplasia, bone erosion and levels of the proinflammatory cytokines TNF-alpha, IL-6 and IL-17A, but not IL-10 in paw tissues.	alantolactone	22-35	interleukin 6	Mus musculus	228-232	
34202301-8	2021	Furthermore, alantolactone treatment in mice significantly alleviated the severity of skin lesions (erythema, scaling and epidermal thickness, and inflammatory cell infiltration) and decreased the mRNA expression of inflammatory cytokines (e.g., TNF-alpha, IL-6, IL-1beta, IL-8, IL-17A, and IL-23) in an IMQ-induced-like mouse model.	alantolactone	13-26	interleukin 6	Mus musculus	257-261